ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1149

Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)

Kirsten Minden1, Martina Niewerth2, Jens Klotsche3, Michael Hammer4, Johannes Peter Haas5, Gerd Ganser6 and Gerd Horneff7, 1Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany, 2Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, 4Klinik fuer Rheumatologie, St. Josef-Stift, Sendenhorst, Germany, 5German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 6Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 7Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: drug therapy, juvenile arthritis and longitudinal studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Etanercept (Eta) has been the most frequently used biologic drug in patients with JIA. In Germany, about one in three patients with polyarticular JIA received Eta in 2010. However, published data on its long-term safety are limited. The data of the German JIA biologic registers BiKeR and JuMBO were used to determine the rates of serious adverse events or events of special interest in order to assess the long-term safety of Eta.

Methods: Patients who were included at start with Eta in the BiKeR registry until March 2007 and have been half-yearly observed into adulthood were considered for this analysis. All adverse events recorded by physicians over the whole observation period (mean 7.5 years) were categorized on the basis of MedDRA. Total exposure-adjusted rates for serious adverse events (SAEs) and for events of special interest (i.e., deaths, malignancies, medically important infections [MII], and newly emerged other immune-mediated inflammatory diseases [IMID]) per 100 patient years (PY) were calculated.

Results: During the 1,815 years of Eta exposure in 386 patients (mean age 23 years, mean disease duration 14 years) 77 SAEs were recorded (4.2 SUEs/100 PY), of which 8% were possibly related to therapy. The SAE rates for each year of Eta exposure per 100 PY varied somewhat over the first nine years of treatment, but did not differ significantly (p=0.312). The JIA-associated mortality rate was 1% in this study population. Two deaths occurred in patients treated with Eta within the last three months before death, but no patient died in suspected causal relationship to Eta. Two malignancies were reported (that were already published1), resulting in 0.11 event per 100 PY of exposure. Twenty MII were recorded which led to drug discontinuation in five patients. 75% of the MII occurred within the first three years of Eta treatment. The exposure-adjusted MII rate was 1.1 per 100 PY. Tuberculosis or other opportunistic infections were not registered. A total of 17 incident IMID (0.9/100 PY) were reported: among them were eight cases with new onset inflammatory bowel disease (0.44/100 PY) and eight cases with uveitis (0.44/100 PY).

Conclusion: The hitherto most comprehensive study of the long-term safety of Eta confirms the good tolerability of the substance. SAEs with possible relationship to therapy occur only rarely (0.3/100 PY). However, reliable risk rates for events of particular interest can only be calculated in larger patient cohorts. Moreover, a comprehensive control group is necessary to put the results into perspective.

Reference: 1 – Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011;50:230-6.


Disclosure:

K. Minden,

Pfizer Inc,

2,

Pfizer Inc, Abbott, Novartis, Chugai, Roche, Medac,

5;

M. Niewerth,
None;

J. Klotsche,
None;

M. Hammer,
None;

J. P. Haas,

Abbott, Novartis, Chugai ,

5;

G. Ganser,

Pfizer, Abbott, Chugai, Actelion,

5;

G. Horneff,

Abbott, Pfizer,

2,

Abbott, Pfizer, Novartis, Chugai, Swedish orphan,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-of-etanercept-in-patients-with-juvenile-idiopathic-arthritis-jia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology